Using 1-[N, O-Bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine) (KN-62), a specific CaMKII antagonist, Williams, et al. [52] observed that blockade of CaMKII activity inhibited the exponentially proliferative capacity of SCLC cells through ameliorating cell cycle arrest at S phase. This evidence concerns the gene CAMK2G and small cell lung carcinoma.